Chronic hepatitis C patients in Taiwan rarely received antiviral treatment due to its high cost and adverse effects until October 2003, when patients with abnormal serum ALT (>2×upper limit normal) and moderate fibrosis proven by liver biopsy (≧Metavir F2 or Ishak F3) could be reimbursed for treatment by the National Health Insurance. The gene discussed is GPT; the disease is fibrosis.